|
DCF -Bewertung der Knochenbiologics Corporation (BBLG)
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Bone Biologics Corporation (BBLG) Bundle
Unser (BBLG) DCF-Taschenrechner entwickelt für Genauigkeit und ermöglicht es Ihnen, die Bewertung der Bone Biologics Corporation anhand von Finanzdaten mit realer Welt zu bewerten, sowie die vollständige Flexibilität, um alle wesentlichen Parameter für verbesserte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -.8 | .0 | .0 | .5 | -4.2 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | 1.1 | 3.7 | 9.4 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -.8 | -1.1 | -3.7 | -8.9 | -4.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | .0 | 6.7 | 7.5 | 3.0 | 3.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | -.6 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .5 | .1 | .1 | .4 | .0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -.8 | -1.1 | 1.7 | -8.9 | -4.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -.4 | -.4 | 6.0 | .2 | -4.6 | .0 | .0 | .0 | .0 | .0 |
| WACC, % | 7.9 | 7.9 | 7.9 | 7.9 | 7.9 | 7.9 | 7.9 | 7.9 | 7.9 | 7.9 |
| PV UFCF | ||||||||||
| SUM PV UFCF | .0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | 3 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | 2.19 |
What You Will Get
- Real BBLG Financial Data: Pre-filled with Bone Biologics Corporation’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Bone Biologics Corporation’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Bone Biologics Corporation’s (BBLG) historical financials and projected forecasts.
- Customizable Assumptions: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Analysis: Instantly view the recalculated intrinsic value of Bone Biologics Corporation (BBLG).
- Intuitive Visualizations: Dashboard charts present valuation outcomes and essential metrics clearly.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file for Bone Biologics Corporation (BBLG).
- Step 2: Review the pre-filled financial data and forecasts for Bone Biologics Corporation (BBLG).
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for Bone Biologics Corporation (BBLG)?
- Designed for Experts: A sophisticated tool tailored for researchers, investors, and healthcare professionals.
- Comprehensive Data: Bone Biologics' historical and projected financials are preloaded for enhanced precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for analyzing Bone Biologics Corporation (BBLG) investments.
- Biotech Research Teams: Evaluate valuation scenarios to inform research and development strategies.
- Financial Consultants: Offer clients precise valuation insights for Bone Biologics Corporation (BBLG) stock.
- Students and Educators: Utilize real-world data to learn and teach financial modeling in the biotech sector.
- Industry Analysts: Gain insights into how biotech companies like Bone Biologics Corporation (BBLG) are valued in the market.
What the Template Contains
- Pre-Filled DCF Model: Bone Biologics Corporation’s (BBLG) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Bone Biologics Corporation’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.